ClinicalTrials.gg
CompletedNCT06229080SEGWAYUpdated Feb 12, 2026

Short-term Embolization Using Gelatin Particles for FloW ModulAtion During Y90 Radioembolization

An interventional study of NexGel in Liver Cancer (Primary and Metastatic), sponsored by Next Biomedical Co., Ltd.. Completed at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Next Biomedical Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Mar 2023, registered Jan 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Liver Neoplasms with a site in Korea, Republic of — 12 open to participants now, 22 under way, 4 of them phase 3. Liver Neoplasms · Korea, Republic of.

Enrollment
64th of 68
20 · median 125
Started
2023
with 4 others
No phase
8 of 78
none open now
Registered
68th of 78
by date

Among the 78 studies in Liver Neoplasms with a site in Korea, Republic of, this one is the 64th largest by enrollment of the 68 interventional ones that give a count, is one of 5 that started in 2023, is one of 8 with no phase, and was the 68th registered.

Liver Neoplasms

1,348 studies on the registry are indexed under Liver Neoplasms; 337 are open to participants now.

Browse Liver Neoplasms studies →

Open to participants now

12 of the 78 studies in Liver Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 244 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 70 (29%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Liver Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The SEGWAY trial is a prospective, single-arm clinical study to evaluate the efficacy and safety of flow diversion to protect non-tumorous liver function using short-acting gelatin sponge particles during Yttrium-90 radioembolization of liver cancer.

Read the detailed description

Short-acting gelatin sponge particles will be used during radioembolization to protect normal liver tissue in patients with liver cancer whose treatment field encompasses a substantial portion of non-tumorous liver tissue. Recanalization of the embolized hepatic artery will be assessed by angiography within 30 minutes following the procedure. Suppression of Y90 microsphere delivery to the protected, non-tumorous liver tissue will be evaluated using Y90 PET-CT imaging, by comparing the protected regions to non-protected, non-tumorous regions within the perfused area. Enhanced tumor uptake of Y90 microspheres will be quantified using the tumor-to-normal liver ratio (TNR), calculated by comparing pre-procedure SPECT-CT with post-procedure PET-CT data. Finally, preservation of liver function in protected tissue relative to unprotected tissue will be assessed six months post-procedure using signal intensity ratios on hepatobiliary phase images obtained from gadoxetic acid-enhanced MRI.

03

Conditions studied

  • Liver Cancer (Primary and Metastatic)
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 19 years or older
  2. Patients diagnosed with primary or liver cancer based on histological and/or radiological findings
  3. Patients determined, following medical, surgical, or multidisciplinary evaluation, to be best treated by radioembolization
  4. Patients with no history of local treatments (e.g., ablation, chemoembolization) to the same hepatic lobe within the past year
  5. class A
  6. (ECOG) performance status of 2 or lower
  7. Patients whose treatment area, as determined by planning angiography, includes at least two liver segments
  8. Patients for whom normal liver tissue constitutes 50% or more of the treatment volume

Exclusion criteria

Exclusion Criteria:

  1. Liver cancer with vascular invasion
  2. For primary liver cancer, patients who have been diagnosed with a other than the primary liver cancer within 2 years prior to study enrollment
  3. Patients who have undergone biliary-enteric anastomosis
  4. Patients with an estimated lung dose of 30 Gy or higher on pre-procedure 99mTc-MAA imaging
  5. Patients with a known to gelatin use
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Test group

    short-acting gelatin sponge particles (NexGel) will be administered to the hepatic arteries toward the non-tumorous liver.

    Device: NexGel

Interventions

  • DeviceNexGel

    When a planned perfused area includes two or more Couinaud segments and more than 50% of the target area is non-tumorous liver, short-acting gelatin sponge particles (NexGel) will be administered to the hepatic arteries toward the non-tumorous liver. The embolization particles will be prepared by mixing one vial of the particles with 5 mL of iodinated contrast agents and intra-arterially delivered with a microcatheter 2.0-Fr or larger. After confirming the disappearance or substantial reduction of liver parenchymal staining of the embolized area on angiography, radioembolization using Y90 glass or resin microspheres will be conducted. Digital subtraction angiography will be performed 30 minutes after the transient embolization to identify recanalization of the transiently embolized hepatic arteries.

06

What researchers measure

Primary outcomes

  1. Mean absorbed dose ratio between the protected perfused liver and unprotected perfused liver

    Mean absorbed dose ratio between the protected perfused liver and unprotected perfused liver

    Time frame: Day 1, The day after radioembolization

Secondary outcomes

  1. Angiographic recanalization of the transiently embolized hepatic arteries

    Angiographic recanalization of the transiently embolized hepatic arteries (grade 0, completely occluded; grade 1, antegrade flow visible only near the RGM injection point; grade 2, sluggish antegrade flow visible to the periphery; and grade 3, completely patent)

    Time frame: After Y-90 microsphere infusion, 30 minutes after embolization

  2. Tumor-to-normal liver ratio change between the pre-treatment SPECT-CT (99mTc-MAA injection without transient embolization) and post-treatment PET-CT (Y90 injection with transient embolization)

    Tumor-to-normal liver ratio change between the pre-treatment SPECT-CT (99mTc-MAA injection without transient embolization) and post-treatment PET-CT (Y90 injection with transient embolization)

    Time frame: Day 1, The day after radioembolization

  3. Ratio of the Relative volumetric changes between the protected perfused liver and unprotected perfused liver

    Ratio of the Relative volumetric changes between the protected perfused liver and unprotected perfused liver

    Time frame: 6 months after radioembolization

  4. Relative signal intensity ratio between the protected perfused liver and unprotected perfused liver on a 20-minute delayed scan of gadoxetic acid-enhanced MRI

    Relative signal intensity ratio between the protected perfused liver and unprotected perfused liver on a 20-minute delayed scan of gadoxetic acid-enhanced MRI

    Time frame: 6 months after radioembolization

  5. Response to the treatment, as assessed by mRECIST

    Objective Tumour Response will be assessed by the investigators on CT/MRI image analysis

    Time frame: 6 months after radioembolization

  6. Serious adverse event

    Serious adverse event

    Time frame: For 6 months from radioembolization

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, 03080, South Korea
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Jan 2025, 22 months.

Of 168 interventional studies with no phase under Liver Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 72. This study's 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2024
First posted
Jan 29, 2024
StartActual
Mar 15, 2023
Primary completionActual
Jan 20, 2025
CompletionActual
Jul 30, 2025
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06229080
Lead sponsor
Next Biomedical Co., Ltd.
Responsible party
Sponsor
First posted
Jan 29, 2024
Start date
Mar 15, 2023
Primary completion
Jan 20, 2025
Completion
Jul 30, 2025
Last update
Feb 12, 2026

Study contacts

Jin Woo Choi
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion